130 results
6-K
EX-99.1
BPTS
Biophytis
14 May 24
Biophytis announces the design of its phase 2 OBA clinical study in obesity
10:28am
, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks
6-K
EX-99.1
BPTS
Biophytis
29 Apr 24
Biophytis is deploying its partnership strategy in obesity
12:47pm
be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks
6-K
EX-99.1
BPTS
Biophytis
25 Apr 24
Biophytis Announces Transfer of ADSs to OTC Market
10:28am
to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject
6-K
EX-99.1
BPTS
Biophytis
19 Apr 24
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
11:16am
proportionally, but the Company can give no assurance that the ADS trading price following the Ratio Change will be at least equal to the ADS trading … on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements
6-K
EX-99.1
BPTS
Biophytis
18 Apr 24
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
10:08am
be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties
6-K
EX-99.1
vz2f2n65nvk8yspmrmw
15 Apr 24
Biophytis files a patent application and strengthens its intellectual property in obesity
10:14am
6-K
EX-99.1
21qjrn0xg98j1gcpz1q
9 Apr 24
Biophytis announces its 2023 financial results
12:25pm
6-K
EX-99.1
5i3np7iz5k rij
9 Apr 24
Biophytis launches OBA phase 2 clinical study
10:46am
6-K
EX-99.1
uwc6zlm07 dwbimg3m3
5 Apr 24
All resolutions presented by the Company have been adopted
10:54am
6-K
EX-99.1
fhj7u214
22 Mar 24
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
12:10pm
6-K
EX-99.1
i9jk5
18 Mar 24
Biophytis announces the implementation
12:51pm
6-K
EX-99.1
o8m4esxf
18 Mar 24
Current report (foreign)
12:46pm
6-K
EX-99.1
am6ku
12 Mar 24
Biophytis announces its participation in several events in Europe and the United States over the coming months
1:06pm
6-K
EX-99.1
guhwnc18k7r e78sc
8 Mar 24
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy
11:20am
6-K
EX-99.1
p69b7nhxq4e19wynllhq
22 Feb 24
Publication of a book on the medicine and science of longevity
2:41pm
6-K
EX-99.1
024eq5
5 Jan 24
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
12:11pm
6-K
EX-99.1
kt2tv26 2x
5 Jan 24
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract
12:09pm